April 28, 2022 -- ProteoNic and NecstGen are partnering to develop improved viral vector manufacturing for gene therapy applications, specifically using adeno-associated virus (AAV) and lentivirus (LV) vectors.
ProteoNic will employ its 2G UNic technology to improve viral vector performance and NecstGen will contribute its viral vector platforms, manufacturing processes, and experts, the firms said.
Copyright © 2022 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
